
5 Business Valuation Questions Every Owner Should Ask
Think your business is worth millions? Think again. A recent survey revealed that 96% of small business owners don't know what their business is actually worth. And most? They overestimate their business valuation, sometimes by six figures or more.
If you're banking your future on selling your business, it's time for a reality check.
In this article, we're cutting through the mistakes, misunderstandings and confusion around small business valuations. I'm answering the five most common questions business owners ask about how valuation. Whether you're looking to sell this year or in three years or never, as a business owner this article will give you the clarity to make smarter, more strategic decisions starting today.
Question 1. 'Why Can't I Just Estimate My Business's Value Based on Revenue or Gut Feel?'
Let's start with the classic: 'My friend sold their agency for 4X revenue. I've worked hard. I know what mine's worth.'
I hear this every week. But here's the truth: your effort, your gut feeling, your desired retirement number,… none of those define market value.
It's not personal. It's just business.
Common (but unreliable) ways business owners guess their business value:
The problem? None of these reflect what a buyer is actually willing to pay.
Every business is different. What sells for 4x profit in one industry might barely scrape 2x in another. Factors like customer churn, owner involvement, recurring revenue, and market risk all matter, often more than revenue or profit itself. If your business can't run without you, it's not as valuable as you think.
Action Step: Separate your business's emotional value from its market value. Then use a valuation method grounded in actual data, not guesswork.
Question 2. 'How Accurate Is a Valuation Tool I Found Online?'
Let's be honest: Free often sounds too good to be true. So how reliable is an online valuation tool, really?
Most owners assume a free valuation is just a gimmick. But not all tools are created equal. For example, the valuation tool I always recommend business owners isn't based on guesswork. It pulls from over 4,500 real-world business exits, totaling more than $30 billion in deals across six continents. It runs your numbers against patterns from actual sales, looking at revenue, profit margins, industry trends, and more.
Does that mean it's a full-blown appraisal? No. But is it a powerful, independent starting point for small business owners? Absolutely.
Action Step: When you use a valuation tool, be honest about your business's profit, industry, customer base, and growth rate. It's not about impressing anyone. It's about getting a real picture of where you stand and what you can improve.
Question 3. 'Why Is My Valuation Lower Than I Expected?'
This one stings. You plug in the numbers, hit 'calculate,' and the result feels like a punch in the gut. If that's you, you're not alone. Most business owners get hit with the same surprise. That's because we tend to overvalue effort and underestimate risk.
Here's what might be decreasing your business value:
The difference between what you hope your business is worth, versus what it is actually worth, is what we call "the value gap'. It's the space between what you think your business is worth and what the market will actually pay.
And it brings us to a powerful insight:
There's a difference between a valuable business and a sellable one.
You might have built something amazing. But if it can't run without you, or if growth has plateaued, buyers see risk and will price accordingly.
Action Step: Take an exit-readiness assessment to identify the biggest factors holding your valuation back. Then use that insight to build a roadmap towards your big exit.
Question 4. 'Can I Trust Business Brokers to Value My Business?'
Short answer: it depends. Here's the reality: Many business brokers make money only when they sell your business. That creates an incentive to inflate the valuation just to win your listing.
And while a higher number might feel good at first, it can backfire fast. Deals fall apart. Buyers walk away. Months are lost. Confidence takes a hit.
The truth is, overpricing your business doesn't increase your chances of a better sale. It often delays the deal or kills it altogether.
Action Step: Always ask brokers to explain their valuation methodology. Better yet, get an independent valuation first, so you walk into those broker conversations with knowledge.
Question 5. 'When Should I Start Thinking About Getting a Business Valuation?'
Too many owners ask this question when it's already too late. 'I'm not selling yet. Should I still bother?' Yes. And here's why.
A business valuation isn't just for those business owners looking to sell their business. It's for smart planners who want options.
Your business valuation tells you how much of your net worth is tied up in the business and how liquid it really is. It shows you what your exit might look like. It helps you spot weaknesses before buyers do. But most importantly, it lets you set clear, strategic goals to build wealth before you're burned out or backed into a corner.
Think of it like a health check-up. You don't wait for a heart attack to start eating better. You get annual blood work, make small changes, and track improvement.
Same with your business.
Action Step: Start treating your valuation like a financial KPI. Check it once a year. See how your strategic efforts are shifting the valuation. That's how real wealth is built: on purpose, not by accident.
Final Thoughts: Know Your Business Valuation, Own Your Future
Business valuation is about numbers and clarity, confidence and control.
When you know what your business is worth, and what's holding that valuation back, you shift from guesswork to leadership. You stop reacting and start engineering your big exit. You get to make choices: Grow or sell. Delegate or hire. Automate or pivot.
It starts by asking the right questions, and being brave enough to face the answers. Because knowing your business valuation? That's the first step to owning your future.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 3, Morgan Stanley analyst Sean Laaman assumed coverage of Axsome Therapeutics, Inc. (NASDAQ:AXSM) with an Overweight rating and a $190 price target. The firm stated that the base case for the rating is the expected on-time supplemental New Drug application Submission for AXS-05 in Alzheimer's Disease Agitation. According to the analyst, it has a high probability of regulatory success and may lead to a potential $900 million in sales by 2030. A pharmacist preparing a prescription for a rapidly absorbed multi-mechanistic medicine. He further stated that the continued launch progress of Auvelity in major depressive disorder is another positive factor for Axsome Therapeutics, Inc. (NASDAQ:AXSM). The analyst told investors in a research note that this growth trajectory is anticipated to continue, supported by market penetration strategies and an expanded sales force. Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a commercial-stage biopharmaceutical company that develops and delivers therapies for central nervous system conditions with limited treatment options. Its two commercial products and development programs include Auvelity and Sunosi. Auvelity treats major depressive disorder (MDD), and Sunosi is an oral medication for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. While we acknowledge the potential of AXSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
13 minutes ago
- Yahoo
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31
Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 23, Citizens JMP analyst Roy Buchanan reiterated a Buy rating on Dynavax Technologies Corporation (NASDAQ:DVAX) and set a price target of $31.00. A biopharmaceutical company executive signing a collaboration agreement with a partner. The company reported record net product revenue for HEPLISAV-B in fiscal Q1 2025, reaching $65 million and showing a 36% year-over-year growth. HEPLISAV-B is the first and only adult vaccine for hepatitis B approved in the US, the UK, and the EU. Its total estimated market share in the US rose to around 43%, compared to around 41% in fiscal Q1 2024. Dynavax Technologies Corporation (NASDAQ:DVAX) also announced plans for the new pandemic influenza adjuvant program and Lyme disease vaccine programs to enter clinical development in 2025 and 2027, respectively. In addition, the company expects top-line results in Part 1 of the Phase 1/2 shingles vaccine trial by fiscal Q3 2025. Dynavax Technologies Corporation (NASDAQ:DVAX) is a biopharmaceutical company that discovers, develops, and commercializes novel vaccines and immuno-oncology therapeutics. The company's product pipeline includes HEPLISAV-B, a vaccine for all known subtypes of the hepatitis B virus in adults aged 18 and above. While we acknowledge the potential of DVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.